Last reviewed · How we verify

Cutivate (FLUTICASONE PROPIONATE)

Teva Pharm · FDA-approved approved Small molecule ✓ Verified May 2026 Quality 64/100

Cutivate (generic name: FLUTICASONE PROPIONATE) is a Corticosteroid Small molecule drug developed by Teva Pharm. It is currently FDA-approved (first approved 1990) for Allergic asthma, Allergic rhinitis, Asthma management.

Cutivate, also known as fluticasone, is a small molecule medication used to treat various conditions, including Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, and Pain, among others. It is administered via inhalation and is prescribed per standard of care, with its pharmacokinetics, pharmacodynamics, and safety profile being studied in children.

At a glance

Generic nameFLUTICASONE PROPIONATE
SponsorTeva Pharm
Drug classCorticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved
First approval1990
Annual revenue69

Approved indications

Common side effects

Serious adverse events

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cutivate

What is Cutivate?

Cutivate (FLUTICASONE PROPIONATE) is a Corticosteroid drug developed by Teva Pharm, indicated for Allergic asthma, Allergic rhinitis, Asthma management.

What is Cutivate used for?

Cutivate is indicated for Allergic asthma, Allergic rhinitis, Asthma management, Atopic dermatitis, Bronchospasm Prevention with COPD.

Who makes Cutivate?

Cutivate is developed and marketed by Teva Pharm (see full Teva Pharm pipeline at /company/teva).

What is the generic name of Cutivate?

FLUTICASONE PROPIONATE is the generic (nonproprietary) name of Cutivate.

What drug class is Cutivate in?

Cutivate belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

When was Cutivate approved?

Cutivate was first approved on 1990.

What development phase is Cutivate in?

Cutivate is FDA-approved (marketed).

What are the side effects of Cutivate?

Common side effects of Cutivate include Ear, nose, and throat disorders, Tremor, Headache, Palpitations, Neurology disorders, Muscle injuries. Serious adverse events: Pneumonia, Elevation of hepatic enzymes, Fractures, Keratitis and conjunctivitis.

What is Cutivate's annual revenue?

Cutivate generated approximately $0.0B in annual revenue.

What does Cutivate target?

Cutivate targets Glucocorticoid receptor and is a Corticosteroid.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing